martes, 22 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 25, 2025

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

View original at globenewswire.com
PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff Dublin, Nov…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Immune Checkpoint Inhibitors segment is expected to reach US$1 Billion by 2030 with a CAGR of 8.9%

    80% confidence

  • China is forecasted to grow at an impressive 13.1% CAGR to reach $222.4 Million by 2030

    80% confidence

  • North America and Europe are leading in clinical research and treatment innovation for PD-1 resistant head and neck cancer

    80% confidence

  • The global market for PD-1 Resistant Head and Neck Cancer was valued at US$1.6 Billion in 2024 and is projected to reach US$3 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030

    80% confidence

  • PD-1 resistance in head and neck cancer arises from complex immune evasion mechanisms, including low tumor immunogenicity, impaired T-cell infiltration, and the presence of immunosuppressive microenvironments

    80% confidence

  • The Asia-Pacific region is expanding its research footprint, especially in countries with high incidence of head and neck cancers linked to tobacco and HPV

    80% confidence

  • The Cytotoxic Agents segment is set to grow at 10.3% CAGR over the analysis period

    80% confidence

  • Growth in the PD-1 resistant head and neck cancer market is driven by factors such as expanding clinical recognition of immunotherapy resistance, rising incidence of advanced-stage HNSCC, and strong research momentum around next-generation immune interventions

    80% confidence

  • Availability of genomic and immunological profiling tools is improving patient selection, while regulatory support for breakthrough designations is facilitating trial progression

    80% confidence

  • Tumors with low PD-L1 expression, defective antigen presentation, or enriched T-regulatory cells often fail to respond to checkpoint blockade

    80% confidence

  • The limited durability of response in monotherapy PD-1 regimens is prompting accelerated development of combination therapies targeting multiple immune checkpoints and tumor pathways

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,983
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados
Consulta estos datos → isubstrate.com
PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff — Source | Via News | es.VIA.NEWS